Stock analysts at StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR - Get Free Report) in a research report issued on Wednesday. The brokerage set a "sell" rating on the stock.
Separately, Lake Street Capital initiated coverage on InspireMD in a research note on Wednesday, December 11th. They issued a "buy" rating and a $5.00 price target on the stock.
Get Our Latest Analysis on InspireMD
InspireMD Price Performance
NSPR stock remained flat at $2.70 during midday trading on Wednesday. 180,040 shares of the company's stock traded hands, compared to its average volume of 36,843. The business has a fifty day moving average price of $2.86 and a two-hundred day moving average price of $2.75. InspireMD has a 12-month low of $1.81 and a 12-month high of $3.80. The firm has a market cap of $80.16 million, a PE ratio of -3.60 and a beta of 0.88.
Institutional Trading of InspireMD
Several hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC bought a new stake in shares of InspireMD during the 4th quarter valued at $27,000. Legato Capital Management LLC acquired a new position in InspireMD in the 4th quarter valued at approximately $47,000. Schonfeld Strategic Advisors LLC increased its position in shares of InspireMD by 153.2% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company's stock worth $79,000 after buying an additional 18,233 shares during the period. Northern Trust Corp raised its stake in InspireMD by 103.7% during the fourth quarter. Northern Trust Corp now owns 48,022 shares of the company's stock worth $126,000 after buying an additional 24,452 shares during the last quarter. Finally, Essex Investment Management Co. LLC bought a new stake in InspireMD during the fourth quarter valued at $191,000. 44.78% of the stock is owned by institutional investors and hedge funds.
InspireMD Company Profile
(
Get Free Report)
InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.
See Also
Before you consider InspireMD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InspireMD wasn't on the list.
While InspireMD currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
